Coeptis Therapeutics (NASDAQ:ZSQR) Trading Down 9% – Time to Sell?

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) dropped 9% on Wednesday . The company traded as low as $9.99 and last traded at $10.14. Approximately 93,545 shares were traded during trading, a decline of 2% from the average daily volume of 95,250 shares. The stock had previously closed at $11.14.

Coeptis Therapeutics Price Performance

The company has a market cap of $544.64 million, a price-to-earnings ratio of -4.20 and a beta of -0.22. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.25 and a current ratio of 3.25. The company’s 50 day moving average price is $11.95 and its 200 day moving average price is $13.26.

Coeptis Therapeutics (NASDAQ:ZSQR) last announced its earnings results on Thursday, May 14th. The company reported ($0.65) EPS for the quarter. The business had revenue of $0.11 million during the quarter. Coeptis Therapeutics had a negative return on equity of 92.29% and a negative net margin of 810.04%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Steward Partners Investment Advisory LLC lifted its position in Coeptis Therapeutics by 100.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock valued at $71,000 after purchasing an additional 2,500 shares during the period. Yorkville Advisors Global LP acquired a new position in Coeptis Therapeutics during the 3rd quarter valued at about $140,000. Marshall Wace LLP acquired a new position in Coeptis Therapeutics during the 4th quarter valued at about $259,000. State Street Corp lifted its position in Coeptis Therapeutics by 35.0% during the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock valued at $382,000 after purchasing an additional 6,962 shares during the period. Finally, Geode Capital Management LLC lifted its position in Coeptis Therapeutics by 12.6% during the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock valued at $600,000 after purchasing an additional 4,721 shares during the period. Institutional investors and hedge funds own 13.88% of the company’s stock.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.